<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04149990</url>
  </required_header>
  <id_info>
    <org_study_id>Version 1.4</org_study_id>
    <nct_id>NCT04149990</nct_id>
  </id_info>
  <brief_title>Angiotensin-Neprilysin Inhibition in Diastolic Dysfunction After AMI</brief_title>
  <acronym>ARNiAMI</acronym>
  <official_title>Angiotensin-Neprilysin Inhibition in Diastolic Dysfunction After AMI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jacob Moller</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital Free Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital- Rigshospitalet Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines the effect of Entresto on central hemodynamic parameters during exercise
      in patients with diastolic dysfunction following acute myocardial infarction. Half of the
      patients will receive Entresto and the other half will receive placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients with acute myocardial infraction (AMI) only 25-33% have entirely normal left
      ventricular (LV) systolic and diastolic function. Studies have show that echocardiographic
      signs of increased LV filling pressure (diastolic dysfunction) are associated with poor
      outcome after AMI. The optimal management of this group of patients is currently not known.
      LCZ696 is a novel combination drug consisting of two antihypertensives, sacubitril and
      valsartan. LCZ696 have demonstrated to reduce mortality in patients with systolic heart
      failure. In patients with heart failure with preserved ejection fraction a positive effect
      has been demonstrated on natriuretic peptides and left atrial remodelling when treated with
      LCZ696, further, experimental data suggest inhibition of cardiac fibrosis.

      Hypothesis:

      LCZ696 compared with placebo will improve central hemodynamics (reduce pulmonary capillary
      wedge pressure (PCWP)), and increase cardiac index (CI) during exercise in patients with
      diastolic dysfunction following AMI. A beneficial effect that is attributed to improved
      cardiac remodelling (attenuation of cardiac fibrosis).

      Primary objective To asses the effect of 6 months treatment with LCZ696 compared with placebo
      on ratio of PCWP/CI during exercise in patients with a recent AMI and Doppler
      echocardiographic signs of diastolic dysfunction and preserved systolic function.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 12, 2018</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Central hemodynamics</measure>
    <time_frame>26 weeks</time_frame>
    <description>The primary endpoint will be the ratio of mean PCWP at peak exercise divided by cardiac index at peak exercise.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cardiac MRI</measure>
    <time_frame>26 weeks</time_frame>
    <description>Amount of hyperenhancement on cardiac MRI using a semiquantitative assessment of late gadolinium hyperenhancement in a 17 segment model of the LV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker</measure>
    <time_frame>26 weeks</time_frame>
    <description>ST2 concentration at rest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker</measure>
    <time_frame>26 weeks</time_frame>
    <description>MR-proANP at rest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker</measure>
    <time_frame>26 weeks</time_frame>
    <description>NT-proBNP at rest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic</measure>
    <time_frame>26 weeks</time_frame>
    <description>Left atrial volume by echocardiography and left atrial emptying fraction by echocardiography at rest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic</measure>
    <time_frame>26 weeks</time_frame>
    <description>Proportion of patients with moderate or severe diastolic dysfunction at rest.echocardiography at rest.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Diastolic Dysfunction</condition>
  <arm_group>
    <arm_group_label>Entresto</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Combination of valsartan and sacubitril titrated to 103+97 mg B.I.D. for 26 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo B.I.D. for 26 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan+ sacubitril</intervention_name>
    <description>Treatment with Entresto(valsartan+sacubitril)</description>
    <arm_group_label>Entresto</arm_group_label>
    <other_name>Entresto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Matching placebo treatment</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Documented ST segment elevation or non ST- myocardial infarction according to current
             guidelines

          2. Complete revascularization

          3. Age ≥50 years

          4. LVEF ≥45% on echocardiography performed within 72 hours of the MI.

          5. Diastolic dysfunction defined as: Ratio of early diastolic peak mitral inflow velocity
             (E) to early mitral annulus diastolic velocity (e') ratio &gt; 8 and at least moderate LA
             dilatation (LA volume index&gt;34 mL/m2).

          6. Signed informed consent

        Exclusion Criteria:

          1. Intolerance towards study medication

          2. Permanent atrial fibrillation,

          3. Known history of cardiomyopathy,

          4. More than mild valvular heart disease,

          5. Severe obstructive or restrictive pulmonary disease,

          6. Inability to perform exercise testing,

          7. Inadequate acoustic windows on echocardiography,

          8. Ongoing treatment with an angiotensin converting enzyme inhibitor at randomization.

          9. Class I indication for an angiotensin converting enzyme inhibitor

         10. Symptomatic hypotension, a systolic blood pressure of less than 100 mm Hg at screening

         11. An estimated glomerular filtration rate (eGFR) below 30 ml per minute per 1.73 m2 of
             body-surface area at any time,

         12. A serum potassium level of more than 5.2 mmol per liter at screening,

         13. A history of hereditary or idiopathic angioedema or unacceptable side effects during
             receipt of angiotensin converting enzyme inhibitor or angiotensin receptor blocker

         14. Inability to provide informed consent

         15. Concomitant use of drugs containing aliskiren in patients with diabetes mellitus.

         16. Severe reduced liver function, biliary cirrhosis or cholestasis (Child-Pugh class C)

         17. Pregnant or nursing(lactating) women(see section 8.2.1 for details)

         18. Fertile women unless they are using a highly effective method of contraception(see
             section 8.2.2 for details)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Cardiology, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Finn Gustafsson</last_name>
      <email>Finn Gustafsson &lt;Finn.Gustafsson@regionh.dk&gt;</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Cardiology, Odense Universityhospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Frederiksen, MD</last_name>
      <phone>+4524672970</phone>
      <email>peter.hartmund.frederiksen@rsyd.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 31, 2019</study_first_submitted>
  <study_first_submitted_qc>October 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2019</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Jacob Moller</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>LCZ 696</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 30, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT04149990/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

